To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Arms Length Body Publication (NHS Standard Contract)
NHS England

Jan. 30 2026

Source Page: NHS Standard Contract 2026/27 consultation response
Document: NHS Standard Contract 2026/27 consultation response (PDF)
Arms Length Body Publication (Guidance)
NHS England

Jan. 30 2026

Source Page: Clinical audits and registries: A best practice guide
Document: Clinical audits and registries: A best practice guide (webpage)
Arms Length Body Publication (Report)
NHS England

Jan. 29 2026

Source Page: Independent Patient Choice and Procurement Panel review of a proposed contract award: Provision of community dermatology services in Greater Manchester
Document: Review of a proposed contract award for provision of community dermatology services in Greater Manchester (webpage)
Arms Length Body Publication (Published)
NICE

Jan. 28 2026

Source Page: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
Publication Type: Summary PDF
Document: Download guidance (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Jan. 28 2026

Source Page: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
Publication Type: Summary PDF
Document: Download (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Jan. 28 2026

Source Page: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
Publication Type: Supporting evidence
Document: Draft guidance committee papers (PDF 14.22 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Jan. 28 2026

Source Page: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
Publication Type: Supporting evidence
Document: Final draft guidance committee papers (PDF 1.78 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Jan. 28 2026

Source Page: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
Publication Type: Resource impact
Document: Resource impact template (Excel 2.29 MB) (webpage)
Arms Length Body Publication (NHS Standard Contract)
NHS England

Jan. 28 2026

Source Page: 2026/27 NHS Standard Contract – Technical Guidance
Document: NHS Standard Contract 2026/27 - Technical guidance (PDF)
Arms Length Body Publication (NHS Standard Contract)
NHS England

Jan. 28 2026

Source Page: Shorter-form NHS Standard Contract 2026/2& (Particulars, Service Conditions, General Conditions)
Document: NHS Standard Contract 2026/27 - Particulars (shorter form) (webpage)